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Abstract This study examines whether renin-angiotensin-
aldosterone system gene polymorphisms: ACE (encoding
for angiotensin converting enzyme) c.2306-117_404 I/D,
AGTR1 (encoding for angiotensin II type-1 receptor)
c.1080*86A>C and CYP11B2 (encoding for aldosterone
synthase) c.-344C>T are associated with the extension of
coronary atherosclerosis in a group of 647 patients who
underwent elective coronary angiography. The extension
of CAD was evaluated using the Gensini score. The poly-
morphisms were determined by PCR and RFLP assays. The
associations between genotypes and the extent of coronary
atherosclerosis were tested by the Kruskal-Wallis test, fol-
lowed by pairwise comparisons using Wilcoxon test. The
population has been divided into groups defined by: sex,
smoking habit, past myocardial infarction, BMI (>, ≤ 25),
age (>, ≤ 55), diabetes mellitus, level of total cholesterol
(>, ≤ 200 mg/dl), LDL cholesterol (>, ≤ 130 mg/dl),
HDL cholesterol (>, ≤ 40 mg/dl), triglycerides (>, ≤
150 mg/dl). Significant associations between the ACE
c.2306-117_404 I/D polymorphism and the Gensini score
in men with high total cholesterol levels (PKruskal-Wallis0
0.008; Padjusted00.009), high level of LDL cholesterol
(PKruskal-Wallis00.016; Padjusted00.028) and low level of
HDL cholesterol (PKruskal-Wallis00.04; Padjusted00.055)
have been found. No association between the AGTR1
c.1080*86A>C and CYP11B2 c.-344C>T and the Gensini
score has been found. These results suggest that men
who carry ACE c.2306-117_404 DD genotype and have
high total cholesterol, high LDL cholesterol and low
Introduction
Coronary artery disease (CAD) is a major public health prob-
lem in many industrialized countries and remains the leading
cause of death in most of them. The renin-angiotensin-
aldosterone system (RAAS) is a well-described hormone sys-
tem that regulates blood pressure and salt/water homeostasis.
RAAS dysfunction contributes to functional and structural
perturbations that occur in atherosclerosis formation (Farmer
and Torre-Amione 2001).
The studies investigating the relation between the RAAS
gene polymorphisms and CAD progression are designed
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HDL cholesterol levels may be predisposed to the devel-
opment of more severe CAD.
Keywords ACE.AGTR1.Atherosclerosis.CAD.
CYP11B2.Gensiniscoreeither to search for an association between the polymor-
phisms and the atherosclerosis severity represented by the
chosen scale of arterial narrowing (e.g. Gensini, jeopardy,
Leaman’s, number of vessels narrowed at least in 50% or
75%), which is the approach we applied, or to evaluate the
CAD risk associated with the presence of specific genotype
in case-control studies, the approach that prevails.
The most studied and clinically important polymorphism
in the angiotensin converting enzyme gene (ACE)i sa n
insertion/deletion (I/D) of a 288 bp Alu repeat sequence
within the intron 16 (ACE c.2306-117_404, rs4340). ACE
c.2306-117_404 I/D polymorphism has been suggestedtobe
related to approximately 50% of the variability in the ACE
levels in the bloodstream, with the highest values present
among DD homozygotes (Rigat et al. 1990). Further, the
ACE c.2306-117_404 I/D polymorphism has been widely
investigated as a CAD risk factor (Zintzaras et al. 2008;
Agerholm-Larsen et al. 2000). An association between this
polymorphism and the extent of coronary atherosclerosis has
been reported for populations ranging from 152 to 1162
participants (Ye et al. 2003;M e n d o n c ae ta l .2004;N i e m i e c
et al. 2008a;H i b ie ta l .1997), although other studies did not
report such an association (Jeunemaitre et al. 1997;N a k a u c h i
et al. 1996; Qiu et al. 2007; Foy et al. 1997; van Geel et al.
2001).
The 1166A>C substitution within the 3‘ untranslated
region of the angiotensin II type-1 receptor gene (AGTR1
c.1080*86A>C, rs5186) occurs in a cis-regulatory region
recognized by a specific microRNA-155 (miR-155) (Martin
et al. 2007). For the C allele, the base-pairing complemen-
tarity of miR-155 and the AGTR1 transcript is interrupted,
thus decreasing the ability of miR-155 to interact with
the cis-regulatory site, which results in miR-155 being no
longer an attenuator of translation, which further leads to a
higher expression of AGTR1 (Martin et al. 2007). It has
been demonstrated that AGTR1 expression is significantly
increased in the CC homozygotes in comparison to AA and
AC genotype carriers (Ceolotto et al. 2011). The AGTR1
c.1080*86A>C polymorphism has been investigated as a
CAD risk factor (Xu et al. 2010). Further, the correlation
between the AGTR1 c.1080*86A>C polymorphism and
the extension of CAD has been found by some (Nakauchi
et al. 1996; Qiu et al. 2007) (study populations of 133 and
130 participants, respectively), but not by all investigators
(Gardemann et al. 1998; van Geel et al. 2001; Jeunemaitre
et al. 1997) (study populations ranging from 463 to 2244
participants).
The aldosterone synthase gene (CYP11B2) polymor-
phism (CYP11B2 c.-344C>T, rs1799998) is located within
the steroidogenic factor-1 (SF-1) binding site, thus SF-1
binding capability has been suggested to vary between the
alleles, although this hypothesis has not been finally con-
firmed (White and Rainey 2005) and thus the potential
biological functionality needs to be yet determined. To our
knowledge, the association between the CYP11B2 c.-344C>T
polymorphism and the extent of atherosclerosis in CAD
has not been reported; however the CYP11B2 c.-344C>T
polymorphism has been related to the severity of atheroscle-
rotic plaque size inthe carotid artery (Sharma and Katz 2010).
Previously the relationship between the CYP11B2 c.-344C>T
polymorphism and hypertension (Sookoian et al. 2007)h a s
been extensively studied. Also, to date, either the T (Casiglia
et al. 2005) or C allele (Tsukada et al. 2002) have been
reported to be risk factors in cardiovascular events. However,
a study finding no relation has also been published (Payne
et al. 2004).
The aim of the present study was to examine whether
three common RAAS genes polymorphisms: ACE c.2306-
117_404 I/D, AGTR1 c.1080*86A>C and CYP11B2
c.-344C>T are associated with the extension of coronary
atherosclerosis, represented by the Gensini score, which is
a reliable estimate of the severity of coronary artery stenosis
(Gensini 1983), in a relatively large cohort of 647 Polish-
Caucasianpatientsundergoingelectivecoronaryangiography.
Materials and methods
Subjects
The patients were admitted to the First Department of Cardi-
ology, Medical University of Gdansk, Poland, between 2005
and 2007 for elective coronarography due to CAD. The
patients were on pharmacological treatment prior to the coro-
narography. Further, only those patients who had undergone
first-time coronary angiography for suspected CAD were
included. The resultant study population consisted of 647
consecutive patients (368 males, 279 females).
Fasting blood samples were tested for levels of: total
cholesterol, high-density lipoprotein (HDL) cholesterol and
triglycerides (TG) with the use of standard enzymatic-
colorimetric methods. The low-density lipoprotein (LDL)
cholesterol level was calculated according to the Friedewald
formula. Smoking habit (smoker, non-smoker, ex-smoker)
was self-reported by study participants. All subjects were
Polish Caucasians and gave their written informed consent
to take part in this study. The study was approved by the
Ethical Committee of the Medical University of Gdansk,
Poland.
Estimation of the severity of coronary stenosis
The patients underwent coronary angiography in accordance
with standard protocols. The severity of CAD was evaluated
by Gensini scores determined by examining coronary angio-
grams. Gensini score is a point scale, which is based on the
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of its luminal narrowing and the localization of the stenosis
(Gensini 1983). Thus the Gensini score is calculated as a sum
of stenosis scores and functional significance scores calculat-
ed for each segment of the coronary artery tree. Stenosis score
expresses the percentage of the reduction in the diameter of
the coronary artery lumen (the score was given from 1 to 32
for complete occlusion). The functional significance score
illustrates the regional importance of the lesion’s position
(the score was given from 0.5 to 5). Gensini score
equals 0 if there is no stenotic change in any of the coronary
arteries segment whereas the maximal value is achieved for
theoreticaltotalocclusioninthemainsegmentsofthecoronary
artery tree.
Genetic analyses
Genomic DNA was isolated from peripheral blood lympho-
cytes in accordance with a standard phenol-chloroform
method.
A polymerase chain reaction (PCR) assay was performed
to detect the ACE c.2306-117_404 I/D polymorphism. The
primer sequences were modified from Rigat et al. (1992):
forward (5‘-CTGGAGACCACTCCCATCCTT-3’), reverse
(5‘-GATGTGGCCATCACATTCGTC-3’). PCR reactions
were performed in a final volume of 10 μl. Each PCR tube
contained: 30 ng of genomic DNA template, 0.2 μM of each
primer, 200 μM of each dNTP, 2 μM MgCl2,1μlo f1 0 ×
PCR buffer (Fermentas, Lithuania) and 0.5 U of Taq DNA
polymerase (Fermentas, Lithuania). The thermocycling con-
ditions were as follows: 95°C for 5 min, 30 cycles of 95°C
for 30 s, 63°C for 1 min and 72°C for 2 min, followed by
final extension at 72°C for 15 min. The shorter D allele
could be preferentially amplified and thus, to avoid mistyp-
ing of ID heterozygotes as DD homozygotes, whenever a
DD genotype was found a confirmatory PCR reaction was
performed, with primers specific for the insertion sequence:
(forward 5‘-TGGGACCACAGCGCCCGCCACTAC-3’)
and reverse (5‘-TCGCCAGCCCTCCCATGCCCATAA-3’)
(Lindpaintner et al. 1995). The second PCR was performed
with the same conditions except the inclusion of 10% dime-
thylsulfoxide (DMSO). The first PCR products were:
490 bp (for I allele) and 202 bp (for D allele). The second
PCR products were: 337 bp (for I allele). PCR products
were separated in 2% agarose gels, stained with ethidium
bromide.
The AGTR1 c.1080*86A>C polymorphism was detected
by PCR/restriction fragment length polymorphism (RFLP)
assay. The PCR primer sequences were as follows: forward
(5‘-GGATGTATTGATTCAACTAGGCATC-3’), reverse
(5‘-AAAGTCGGTTCAGTCCACATAATGC-3’). PCR
reactions were performed in a final volume of 20 μl and
contained 60 ng of genomic DNA template, 0.2 μM of each
primer, 200 μM of each dNTP, 2 μM MgCl2,2μlo f1 0 ×
PCR buffer (Fermentas, Lithuania) and 0.75 U of Taq DNA
polymerase (Fermentas, Lithuania). The thermocycling con-
ditions were as follows: 95°C for 5 min, 35 cycles of 95°C
for 30 s, 58°C for 30 s and 72°C for 1 min, followed by
72°C for 10 min. The 437 bp PCR products were digested
with 4 U of HpyF3I (DdeI isomer) restriction endonuclease
(Fermentas, Lithuania) for 18 h at 37°C. The resulting restric-
tion products were: 240 bp, 200 bp for the AA genotype;
240 bp, 200 bp, 140 bp, 60 bp for the AC genotype and
240 bp, 140 bp, 60 bp for the CC genotype. PCR and
RFLP products were separated in 3% agarose gels, stained
with ethidium bromide.
The CYP11B2 c.-344C>T polymorphism was detected
by PCR/RFLP assay. The PCR primer sequences were as
follows: forward (5‘-CTGTGGTGGAGGGTGTACCT-3’),
reverse (5‘-TCCAGGGCTGAGAGGAGTAA-3’). PCR
reactions were performed in a final volume of 25 μl. Each
PCR tube contained: 30 ng of genomic DNA template,
0.4 μM of each primer, 200 μM of each dNTP, 1.5 μMo f
MgCl2, 2.5 μl of 10×PCR buffer (Fermentas, Lithuania)
and 0.5 U of Taq DNA polymerase (Fermentas, Lithuania).
The thermocycling conditions were as follows: 95°C for
5 min, 35 cycles of 95°C for 30 s, 59°C for 30 s and 72°C
for 20 s, followed by 72°C for 7 min. PCR products were
digested with 2 U of BsuRI (HaeIII isomer) restriction
enzyme (Fermentas, Lithuania) with the inclusion of bovine
serum albumin (BSA) for 18 h at 37°C. The resulting
restriction products were: 124 bp, 60 bp for the CC genotype;
184 bp, 124 bp, 60 bp for the TC genotype and 184 bp for the
TT genotype. PCR and RFLP products were separated in 3%
agarose gels, stained with ethidium bromide.
Statistical analyses
The Hardy-Weinberg equilibriums for each of the genotypes
tested were calculated using the chi square test. The relation
of the analyzed polymorphisms and the extent of coronary
atherosclerosis were compared among the groups by the
Kruskal-Wallis test, followed by the Wilcoxon analyses for
comparisons of two groups. P-values were corrected for
multiple comparisons using Bonferroni method, when appro-
priate. The level of statistical significance was set at P<0.05.
All statistical analyses were carried out using the SAS 9.2
package (SAS Institute Inc., Cary, NC, USA).
Results
Clinical and laboratory data of CAD patients including the
atherosclerotic risk factors are summarised in Table 1.T h e
Gensiniscore equals0 for 242 patientsmeaning nosignificant
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angiography was found.
In the population as a whole, the distributions of the
ACE c.2306-117_404 I/D, AGTR1 c.1080*86A>C and
CYP11B2 c.-344C>T genotypes did not significantly
differ from that expected by Hardy-Weinberg equilibrium.
The distributions of Gensini scores were skewed and
could not be normalized by several transformation cal-
culations. Therefore non-parametric and ranked analyses
were chosen.
We found no association between the ACE c.2306-
117_404 I/D, AGTR1 c.1080*86A>C and CYP11B2
c.-344C>T and the severity of coronary artery lesions in
CAD patients in the population as a whole.
Table 1 Clinical and
laboratory data of 647
patients with CAD
*Median (25th-75th quartile)(N)
Gensini score*
All Males Females
10 (0-48) 26 (0-61) 0 (0-28)
(647) (368) (279)
Smoke non-smoker 0 (0-31) 18 (0-53) 0 (0-16)
(240) (75) (165)
ex-smoker 20 (0-56) 28 (2-68) 4 (0-40)
(304) (220) (84)
smoker 18.5 (0-52) 32 (2-62) 5 (0-32)
(84) (62) (22)
Past MI No 2 (0-30) 9.5 (0-42) 0 (0-14)
(433) (222) (211)
Yes 40 (11-86) 46 (22-97) 28 (0-56)
(213) (145) (68)
BMI ≤25 10 (0-48) 31 (2-58) 0 (0-27)
(213) (113) (100)
>25 10 (0-48) 25 (0-66) 0 (0-28)
(434) (255) (179)
Age ≤55 2 (0-32) 18 (0-52) 0 (0-16)
(233) (87) (146)
>55 20 (0-56) 28 (2-69) 4 (0-40)
(414) (281) (133)
Diabetes mellitus No 8 (0-47) 25 (0-60) 0 (0-14)
(495) (282) (213)
Yes 25.5 (3-52.5) 29 (5-62) 20.5 (0-44)
(152) (86) (66)
Total cholesterol ≤200 mg/dl 8 (0-44) 24 (0-58) 0 (0-20)
(409) (249) (160)
>200 mg/dl 16 (0-52) 32 (7-62) 3 (0-40)
(238) (119) (119)
LDL cholesterol ≤130 mg/dl 9 (0-46) 27 (0-64.5) 0 (0-20)
(482) (288) (194)
>130 mg/dl 14 (0-49) 22.5 (4-56) 5 (0-41)
(165) (80) (85)
HDL cholesterol >40 mg/dl 14 (0-53) 30 (0-67.5) 0 (0-32)
(205) (124) (81)
≤40 mg/dl 9 (0-47) 23 (0-57.5) 0 (0-25)
(442) (244) (198)
TG ≤150 mg/dl 7 (0-44) 25 (0-58) 0 (0-22)
(473) (261) (212)
>150 mg/dl 20 (0-56) 30 (6-62) 4 (0-41)
(174) (107) (67)
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and the severity of the disease were examined within groups
created by subdividing the population according to: sex,
smoking habit, past myocardial infarction (MI), BMI (>25,
≤25), age (>55, ≤55), diabetes mellitus, total cholesterol
(>200 mg/dl, ≤200 mg/dl), LDL cholesterol (>130 mg/dl,
≤130 mg/dl), HDL cholesterol (>40 mg/dl, ≤40 mg/dl), TG
(>150 mg/dl, ≤150 mg/dl) levels.
A significant association between the ACE c.2306-
117_404 I/D polymorphism and the extent of coronary
atherosclerosis was found in men with high total cholesterol
levels (>200 mg/dl) (PKruskal-Wallis00.008; PIIvsDallel00.0023;
Padjusted00.009), and also in men with high LDL cholesterol
levels (>130 mg/dl) (PKruskal-Wallis00.016; PIIvsDallel00.007;
Padjusted00.028) and low HDL cholesterol levels (≤40 mg/dl)
(PKruskal-Wallis00.04; PIIvsDallel00.0138; Padjusted00.055),
with the highest values of Gensini score present in the ACE
c.2306-117_404 D allele carriers in comparison to other
genotypes (Table 2). No significant association between the
ACE c.2306-117_404 I/D polymorphism and the extent of
coronary atherosclerosis was found when the population
was analyzed in other subgroups, as listed above (data not
presented).
PKruskal-Wallis00.018 for the association between the
CYP11B2 c.-344C>T polymorphism and the Gensini score
was found in women with high LDL cholesterol levels
(>130 mg/dl). However, after Bonferroni corrections for
multiple comparisons, P-value was no longer statistically
significant (PCCvsTallel00.045; Padjusted00.18) (data not pre-
sented). No significant associations were found between the
CYP11B2 c.-344C>T polymorphism and the Gensini score
in other subgroups either (data not presented).
No significant associations between the AGTR1
c.1080*86A>C polymorphism and the severity of coronary
artery lesion in CAD patients were found in any of the
subgroups analyzed (data not presented).
Discussion
The prominent role of the RAAS in the maintenance of
cardiovascular homeostasis suggests that allelic variants of
genes encoding for the components of this hormone system
could modulate the severity of CAD. This study evaluates
the association of three RAAS gene polymorphisms: ACE
c.2306-117_404 I/D, AGTR1 c.1080*86A>C, CYP11B2
c.-344C>T and the extension of coronary lesions, repre-
sented by Gensini score, which is based on the number of
stenotic coronary artery segments, and a degree of the
luminal narrowing and the regional importance of the
Table 2 Median Gensini score
values defined by the ACE
c.2306-117_404 I/D
genotypes in the whole
population and in subsets
*Median (N)
aPIIvsDD00.0056 for comparison
of ACE c.2306-117_404 II vs.
DD; PIDvsDD00.91 for ID vs.
DD; PIDvsII00.008 for ID vs. II,
PIIvsDallel00.0023 for II vs.
D allel
bPIIvsDD00.007 for comparison
of ACE c.2306-117_404 II vs.
DD; PIDvsDD00.51 for ID vs.
DD; PIDvsII00.03 for ID vs. II,
PIIvsDallel00.007 for II vs. D allel
cPIIvsDD00.08 for comparison of
ACE c.2306-117_404 II vs. DD;
PIDvsDD00.60 for ID vs. DD;
PIDvsII00.014 for ID vs. II,
PIIvsDallel00.0138for II vs. D allel
Genotype: Gensini scale* PKruskal-Wallis
ACE ACE ACE
DD ID II
Whole investigated population 10 (147) 10 (305) 8.5 (180) 0.92
Sex Males 25.5 (84) 31 (173) 23 (100) 0.26
Females 0 (63) 0 (132) 2.5 (80) 0.49
Total cholesterol ≤200 mg/dl All 4 (83) 8 (205) 14 (112) 0.24
Males 9.5 (50) 25 (122) 28.5 (70) 0.29
Females 0 (33) 0 (83) 2.5 (42) 0.46
Total cholesterol >200 mg/dl All 26.5 (64) 17 (100) 4.5 (68) 0.09
Males 37.5 (34) 35 (51) 7 (30) 0.008
a
Females 3 (30) 0 (49) 2.5 (38) 0.74
LDL cholesterol ≤130 mg/dl All 4 (103) 9.5 (236) 10.5 (132) 0.42
Males 16 (61) 32 (138) 28.5 (80) 0.32
Females 0 (42) 0 (98) 1 (52) 0.52
LDL cholesterol >130 mg/dl All 32 (44) 16 (69) 5.5 (48) 0.07
Males 37 (23) 25 (35) 7 (20) 0.016
b
Females 6 (21) 4 (34) 4.5 (28) 0.75
HDL cholesterol >40 mg/dl All 3 (38) 17.5 (106) 26 (56) 0.32
Males 26 (21) 30 (67) 38 (33) 0.34
Females 0 (17) 2 (39) 0 (23) 0.78
HDL cholesterol ≤40 mg/dl All 11 (109) 9 (199) 6 (124) 0.54
Males 25 (63) 31.5 (106) 10 (67) 0.04
c
Females 0 (46) 0 (93) 3 (57) 0.24
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and thus comprises the real reflection of the severity of the
CAD.
The results we present demonstrate an association be-
tween the ACE c.2306-117_404 I/D polymorphism and the
extension of atherosclerosis assessed by the Gensini score,
with values ≥0. The association was found among men with
high total cholesterol levels (>200 mg/dl), high LDL cho-
lesterol levels (>130 mg/dl) and low HDL cholesterol levels
(≤40 mg/dl). Our results suggest that pro-atherosclerotic
actions of angiotensin II are more pronounced when en-
hanced by other systemic mechanisms, such as a long-
lasting exposure to common CAD risk factors.
The importance of ACE in CAD etiology is undisputed.
The chronic influence of higher levels of angiotensin II in
the ACE D allele carriers, in comparison to the I allele
carriers (Jeunemaitre 2008), may concur to the development
and/or progression of atherosclerosis. The enhanced ACE
expression in macrophages and smooth muscle cells of
coronary artery plaques has been previously reported to
indicate that ACE activity in lesions contributes greatly to
the progression of atherosclerosis (Ohishi et al. 1997).
Our results correspond to a few previous studies. An
association between the ACE c.2306-117_404 D allele
and the severity of CAD, described by the number of narrow-
ings of 50% or higher and by the number of critical arterial
occlusions has been reported in a Polish population (Niemiec
et al. 2008a), analyzed as a whole, of 172 young (30-55 years
old) subjects diagnosed with CAD. The scale chosen by
Niemiec et al. (2008a) to assess the severity of CAD does
not include localization of the narrowing involved in the
Gensini scale but requiresincluding atleastone severearterial
narrowing. In a population of 296 patients, Mendonca et al.
(2004) showed that the DD genotype is significantly linked to
the severity of CAD, which has been assessed by the
Leaman’s score measuring the number of arteries with
more than 75% stenosis and thus accounts for severe
changes only. In a population of 1162 subjects Ye et al.
(2003) found that among patients who carry D allele
CAD has been more extensive. The severity of athero-
sclerosis was defined in their study as the number of
coronary segments with 5-75% stenosis so patients with
greater atherosclerotic extension were excluded. Also,
the results of meta-analysis (Sayed-Tabatabaei et al.
2003) investigating the association between the ACE
c.2306-117_404 I/D polymorphism and the carotid artery
intima-mediathickness (IMT),usedtodetectthe presenceand
to follow the progression of atherosclerosis, correspond with
our work. Its authors report a positive association between the
D allele and the carotid IMT, with the association being
stronger among high-risk patients.
Our finding is both sex-specific and related to metabolic
factor. Also, among 11 studies, which included sex
interaction, described in recent meta-analysis (Zintzaras et
al. 2008), six reported positive association between the ACE
c.2306-117_404 I/D polymorphism and CAD in males
only. Zintzaras et al. (2008) suggested the actions of corti-
costeroid hormones affecting the activity of the RAAS
might be involved. Freitas et al. (2008) demonstrated that
the presence of DD genotype increases the risk of develop-
ing CAD when associated to each of classical risk factors:
hypertension, obesity, diabetes and hyperlipidemia consid-
ered as total cholesterol ≥200 mg/dl, TG ≥150 mg/dl, LDL
cholesterol ≥130 mg/dl and HDL cholesterol ≤40 mg/dl.
Investigating a case-control study, Niemiec et al. (2007)
concluded that the presence of the D allele increases the
risk of CAD associated with the presence of hyperlipidemia
defined by total cholesterol ≥5 mmol/l, LDL cholesterol
≥3 mmol/l, TG ≥1,7 mmol/l and overweight/obesity. Hibi
et al. (1997) found that the ACE c.2306-117_404 I/D poly-
morphism correlates with the number of vessels with steno-
sis greater than 75%, with the number of lesions with
stenosis greater than 50% and extent index, calculated on
the basis of percentage of the segment’s length that appeared
abnormal, among smokers. However, the authors did not
find an association within the group with hyperlipidemia
defined as total cholesterol ≥5.7 mmol/l.
Our findings contrast with those from several studies.
It is, however, important to note that the comparisons
between the studies may not be accurate as various
scales were applied for the measurement of atherosclero-
sis progression. No associations between the ACE c.2306-
117_404 polymorphism and the atherosclerosis extent
measured by Gensini score, by the number of coronary
arteries with stenosis greater than 75% (Nakauchi et al.
1996) and using other scales (Qiu et al. 2007; Foy et al.
1997; Jeunemaitre etal. 1997; van Geeletal.2001)h a v eb e e n
reported.
We did not find any associations between the AGTR1
c.1080*86A>C polymorphism and the severity of CAD as
determined by Gensini score either within the whole popula-
tion or in any of the investigated subgroups. Such a result is
supported by a recent meta-analysis (Xu et al. 2010)w h i c h
includes 53 studies. The authors conclude that there is only a
weak association between the AGTR1 c.1080*86A>C poly-
morphismandcoronaryheartdisease.Similarly,noassociation
between the AGTR1 c.1080*86A>C polymorphism and the
Gensini score (Gardemann et al. 1998; Nakauchi et al.
1996), number of arteries stenosed (Gardemann et al.
1998; van Geel et al. 2001) and the angiographic score
(Jeunemaitre et al. 1997) has been found. Interestingly,
Nakauchi et al. (1996) report that among the patients
with the AC genotype the number of arteries narrowed
by 75% was higher than among those carrying the AA geno-
type. Further, Qiu et al. (2007) found that the AGTR1
c.1080*86A>C polymorphism may be involved in the
180 J Appl Genetics (2012) 53:175–182severity of CAD, with the number of stenosed vessels and the
coronary jeopardy score greater in the patients with the AC
genotype than in those with the AA genotype.
Our results are in agreement with those reported by Freitas
et al. (2008), who did not find any association between the
AGTR1 c.1080*86A>C polymorphism and the increased risk
of CAD, also in the context of dislipidemia, defined as total
cholesterol ≥200 mg/dl, TG ≥150 mg/dl, LDL cholesterol
≥130 mg/dl and HDL cholesterol ≥40 mg/dl. However,
Niemiec et al. (2008b) found that the C allele is associated
with a higher risk of CAD in patients with hypercholesterol-
emia (total cholesterol level ≥5 mmol/l).
The association between the CYP11B2 c.-344C>T poly-
morphism and the extent of coronary atherosclerosis has not
been investigated before in patients who had undergone
first-time coronary angiography. In our study, this polymor-
phism has not been associated with the extent of coronary
atherosclerosis directly or via interactions with commonly
knownatherosclerotic riskfactors.Interestingly,the CYP11B2
c.-344C>T polymorphism has been associated with the pro-
gression of atherosclerotic plaque size in the carotid artery
(Sharma and Katz 2010). Our results are in agreement with
previous investigations reporting no association between the
CYP11B2 c.-344C>T polymorphism and bypass degradation
measured by adjusted Gensini score (Ortlepp et al. 2001),
stent restenosis (Ryu et al. 2002), caroid IMT (Balkestein et
al. 2002; Sarzani et al. 2003) and overall CAD events risk in
2490 healthy men (Payne et al. 2004). Therefore, further
studies regarding the association between the CYP11B2
c.-344C>T polymorphism and atherosclerosis progression
would be of interest.
Conclusions
In this study, we investigated the association between
the ACE c.2306-117_404 I/D, AGTR1 c.1080*86A>C and
CYP11B2 c.-344C>T polymorphisms, within the genes
encoding for RAAS proteins, and the extent of atherosclero-
sis. The association was searched in groups of patients, se-
lected according to common CAD risk factors, such as
abnormal lipids profile. Our results suggest that those men
who carry the ACE c.2306-117_404 DD genotype and who
have high total, high LDL or low HDL cholesterol levels
may be more predisposed to the development of more severe
CAD. No association between the AGTR1 c.1080*86A>C
or CYP11B2 c.-344C>T polymorphisms and the extent of
atherosclerosis in CAD has been found.
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